Sichuan Haisco Pharmaceutical Co. Ltd. has developed pyrazinone derivatives acting as protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors. They are reported to be useful for the treatment of cancer.
Sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers have been reported in a Vertex Pharmaceuticals Inc. patent as potentially useful for the treatment of pain, arrhythmia, Charcot-Marie-Tooth disease, cough, urinary incontinence and multiple sclerosis.
Debiopharm Research & Manufacturing SA has disclosed new antibody-drug conjugates consisting of monoclonal antibodies targeting CD37 covalently linked to a cytotoxic agent through a linker.
Work at Suzhou Genhouse Bio Co. Ltd. has led to the discovery of oxadiazole compounds acting as histone deacetylase 6 (HDAC6) inhibitors and thus reported to be potentially useful for the treatment of cancer, asthma, Alzheimer’s disease, diabetes, amyotrophic lateral sclerosis, multiple sclerosis, pulmonary fibrosis and psoriasis, among others.
Humanwell Healthcare (Group) Co. Ltd. has identified new kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer, psoriasis, atopic dermatitis, autoimmune diseases and inflammatory bowel disease.
Nerio Therapeutics Inc. has patented new tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer, type 2 diabetes, obesity and metabolic diseases.
Gasherbrum Bio Inc. patent details heterocyclic glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, among others.
Oncopia Therapeutics Inc. (dba Proteovant Therapeutics Inc.) and the University of Michigan have jointly patented molecular glue degraders targeting cereblon (CRBN) and acting as zinc finger protein Helios (IKZF2) degradation inducers.
Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers have been reported in a Bristol Myers Squibb Co. patent as potentially useful for the treatment of cancer.
RSS